508 related articles for article (PubMed ID: 31618777)
1. Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease.
Naushad M; Durairajan SSK; Bera AK; Senapati S; Li M
Planta Med; 2019 Nov; 85(17):1316-1325. PubMed ID: 31618777
[TBL] [Abstract][Full Text] [Related]
2. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.
Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M
FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692
[TBL] [Abstract][Full Text] [Related]
3. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of 2-amino-imidazol-4-one derivatives as potent β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors.
Fan TY; Wu WY; Yu SP; Zhong Y; Zhao C; Chen M; Li HM; Li NG; Chen Z; Chen S; Sun ZH; Duan JA; Shi ZH
Bioorg Med Chem Lett; 2019 Dec; 29(24):126772. PubMed ID: 31711785
[TBL] [Abstract][Full Text] [Related]
5. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
[TBL] [Abstract][Full Text] [Related]
6. Targeting the β secretase BACE1 for Alzheimer's disease therapy.
Yan R; Vassar R
Lancet Neurol; 2014 Mar; 13(3):319-29. PubMed ID: 24556009
[TBL] [Abstract][Full Text] [Related]
7. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
8. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
9. Identification of new BACE1 inhibitors for treating Alzheimer's disease.
Kushwaha P; Singh V; Somvanshi P; Bhardwaj T; Barreto GE; Ashraf GM; Mishra BN; Chundawat RS; Haque S
J Mol Model; 2021 Jan; 27(2):58. PubMed ID: 33517514
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
12. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
13. Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function.
Zhu K; Peters F; Filser S; Herms J
Biol Psychiatry; 2018 Oct; 84(7):478-487. PubMed ID: 29945719
[TBL] [Abstract][Full Text] [Related]
14. Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease.
Zhang C
Discov Med; 2012 Sep; 14(76):189-97. PubMed ID: 23021373
[TBL] [Abstract][Full Text] [Related]
15. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
16. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
17. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
Kumar A; Roy S; Tripathi S; Sharma A
J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
[TBL] [Abstract][Full Text] [Related]
19. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
20. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]